Reversal of the Antithrombotic Action of New Oral Anticoagulants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants.

1. To determine the effect of new oral anticoagulants (dabigatran and rivaroxaban) on platelets and coagulation mechanisms under flow conditions.
2. To evaluate the ability of the concentrates containing coagulation factors (PCCs and FVIIa) to reverse the effects induced by the new anticoagulants.

These studies will be carried out ex vivo in blood samples obtained from healthy volunteers undergoing oral anticoagulant therapy at doses of proven efficacy and safety used in previous clinical trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics

NCT01210755

Venous Thromboembolism

COMPLETED PHASE4

Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

NCT01704053

Clot Formation and Platelet Aggregation in Point of Care Testing

COMPLETED

Reversal of Dabigatran With Prothrombin Complex Concentrate

NCT02463591

Drug Action Reversal

UNKNOWN PHASE2

Rivaroxaban for Patients With Antiphospholipid Syndrome

NCT02926170

Antiphospholipid Syndrome

COMPLETED PHASE3

A Prospective Pharmacodynamic Study of Rivaroxaban

NCT01743898

Blood Clot

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is a lack of information on antidotes that could reverse the effects of new oral anticoagulants in patients that require a rapid restoration of their impaired hemostatic mechanisms. The present study seeks to improve the security and efficacy of the clinical practice with the new generation of oral anticoagulants.

OBJECTIVES:

1. To assess the action of new oral anticoagulants (dabigatran y rivaroxaban) on hemostasis with specific interest on possible interference with platelet interactions and coagulation mechanisms under flow conditions;
2. To evaluate comparatively the effects of coagulation factor concentrates of established efficacy (prothrombin complexes and rFVIIa) to reverse the alterations of hemostasis parameters induced by the new anticoagulants.

METHODOLOGY:

Studies will be performed ex vivo using blood samples from healthy individuals subjected to treatments with the new anticoagulants at doses of proven efficacy and safety (150mg/12 h for dabigatran and 20 mg/day for rivaroxaban). Blood samples from the participants will be spiked "in vitro" with know concentrations of the coagulation factors. Modifications in:

* morphometric parameters (platelet deposition and fibrin formation) in perfusion studies under flow conditions; and
* analytical tests evaluating changes in coagulation mechanisms (thrombin generation, ecarine and prothrombin times) will be determined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombosis Anticoagulant-induced Bleeding Anticoagulant Overdosage Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rivaroxaban

Healthy donors subjected to 20mg/day for 5 days

Group Type ACTIVE_COMPARATOR

Rivaroxaban

Intervention Type DRUG

20 mg/day, oral administration maintained for 5 days

Dabigatran

Healthy volunteers subjected to 150 mg/12hours for 5 days

Group Type ACTIVE_COMPARATOR

Dabigatran

Intervention Type DRUG

150 mg/12 hours, administered orally, treatment maintained for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban

20 mg/day, oral administration maintained for 5 days

Intervention Type DRUG

Dabigatran

150 mg/12 hours, administered orally, treatment maintained for 5 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xarelto is the brand name for rivaroxaban Pradaxa is the brand name for dabigatran

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers ages from 21 to 60 years
* Approval informed consent

Exclusion Criteria

* History of hepatic or kidney disease
* Previous history of hemorrhagic or thrombotic disease
* Pregnancy or breast feeding
* Concomitant use of drugs affecting hemostasis
* Use of medications of herbal treatments that could interfere with the pharmacokinetics or pharmacodynamics of the study drug (according to manufacturers label)
* Practice of risky sports (during the study period)
* Blood donation in the previous 3 months

Minimum Eligible Age

21 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes